Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Frasier syndrome is characterized by the association of male pseudohermaphrodism and glomerular nephropathy. This syndrome is associated with a high risk of developing gonadoblastoma.
Features include always present findings: Stage 5 chronic kidney disease, Nephrotic syndrome, Gonadal dysgenesis, and Protein in the urine (proteinuria) and others; and very common findings: Hypergonadotropic hypogonadism, Increased circulating gonadotropin level, Decreased serum estradiol, and Gonadal dysgenesis with female appearance, male. 19 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 7 |
WT1 function has not been fully characterized.
Frasier syndrome is associated with mutations in the WT1 gene on chromosome 11.
Recent developments have allowed delineation of genotype-phenotype correlations for certain subgroups of WT1 pathogenic variants (see also Table 1 in ). Truncating pathogenic variants (all nonsense, frameshift, or splice-site variants that are not KTS [lysine, threonine, and serine] intron 9 variants; see ) are associated with the following [, , , ]:
Formal diagnostic criteria for WT1 disorder have not been established. Note: This chapter on WT1 disorder excludes WAGR syndrome (Wilms tumor-aniridia-genital anomalies-range of developmental delays), caused by a contiguous gene deletion of PAX6 and WT1 (see PAX6-Related Aniridia).
WT1 disorder should be suspected in an individual with the following clinical, imaging, and supportive laboratory findings.
Steroid-resistant nephrotic syndrome. A progressive glomerulopathy that does not respond to standard steroid therapy; see and for diagnostic clinical practice guidelines.
No approved treatments are currently available for Frasier syndrome. The disease remains an area of unmet medical need.
See and for clinical practice recommendations for the management of children with steroid-resistant nephrotic syndrome.
To establish the extent of disease and needs in an individual diagnosed with WT1 disorder, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. WT1 Disorder: Recommended Surveillance
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
10 publications have been identified in PubMed for Frasier syndrome. Research spans Review / Meta-Analysis (44%), Case Report / Case Series (44%), and Basic Science / Preclinical (11%).
Khandelwal MH (2026). [PMID: 41884246](https://pubmed.ncbi.nlm.nih.gov/41884246/). *World J Nephrol*. [Case Report / Case Series]
Li C (2025). [PMID: 39037087](https://pubmed.ncbi.nlm.nih.gov/39037087/). *Clin Nephrol*. [Review / Meta-Analysis]
Lu J (2025). [PMID: 39929160](https://pubmed.ncbi.nlm.nih.gov/39929160/). *Kidney Blood Press Res*. [Review / Meta-Analysis]
Costin M (2025). [PMID: 40426774](https://pubmed.ncbi.nlm.nih.gov/40426774/). *Children (Basel)*. [Case Report / Case Series]
Inaba Y (2025). [PMID: 40764872](https://pubmed.ncbi.nlm.nih.gov/40764872/). *CEN Case Rep*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Oct 4, 2026, 3:02 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Frasier syndrome
Hormones | 2 | Primary amenorrhea, Hypergonadotropic hypogonadism |
Heart and blood vessels | 1 | Hypertension |
Age of onset: childhood, adulthood, adolescence.
WT1 disorder is characterized by congenital/infantile or childhood onset of a progressive glomerulopathy that does not respond to standard steroid therapy. Additional common findings can include disorders of testicular development (with or without abnormalities of the external genitalia and/or mllerian structures) and Wilms tumor. Less common findings are congenital anomalies of the kidney and urinary tract (CAKUT), gonadoblastoma, and 46,XX gonadal dysgenesis . In adulthood, most individuals are affected by early gonadal insufficiency of variable severity with potential impact on puberty and fertility.
Source: GeneReviews — "WT1 Disorder"
Source: GeneReviews — "WT1 Disorder"
The penetrance of WT1 disorder is high. It is age dependent, reaching about 90% by the end of puberty. A few asymptomatic parents heterozygous for the same germline WT1 variant in their affected offspring have been reported [, , , , ]. The penetrance appears to depend on the sex of the affected parent, with higher penetrance associated with paternal origin of the WT1 variant . However, current data on penetrance are limited because the variable expressivity of WT1 pathogenic variants was not recognized until recently, and the asymptomatic parents of a child with a WT1 pathogenic variant were not routinely tested.
Source: GeneReviews — "WT1 Disorder"
Source: GeneReviews — "WT1 Disorder"
For the differential diagnosis of:
Steroid-resistant nephrotic syndrome, see Genetic Steroid-Resistant Nephrotic Syndrome Overview;
Wilms tumor, see Wilms Tumor Predisposition;
46,XY disorders of testicular development, see Nonsyndromic Disorders of Testicular Development Overview;
Diaphragmatic hernia, see
Source: GeneReviews — "WT1 Disorder"
Genetic testing for WT1 is available. Testing is considered confirmatory for diagnosis.
WT1 Disorder: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
Glomer-
ulopathy | Persistentproteinuria | Urine protein-to-creatinine ratio | For evidence of proteinuria
SRNSCKDCNS | • 24-hr urine protein test
Serum protein, albumin, creatinine, cholesterol, IgG, C3
Blood pressure measurements
| For evidence of proteinuria, hypertension, CKD1
Disorder of
testicular
development | Karyotype w/FISH for SRY or CMA (to determine chromosomal sex) | To be performed in all persons w/ambiguous genitalia all prepubertal phenotypic females
Pelvic US | Eval of gonadal localization character
Hormonal studies | For children who have not undergone gonadectomy: hormonal studies as directed by pediatric endocrinologist
| Abdominal US | Metachronous synchronous tumors may be unilateral or bilateral.
| Abdominal US | To identify duplex kidney, horseshoe kidney, kidney malrotation, /or signs of obstructive nephropathy due to vesicoureteral reflux ureteropelvic junction stenosis
Diaphragmatic
Source: GeneReviews — "WT1 Disorder"
Avoid treating glomerulopathy with immunosuppressants, as they are not effective and potentially toxic.
Source: GeneReviews — "WT1 Disorder"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "WT1 Disorder"
1 trial found
Evaluation |
|---|
Frequency |
|---|
ulopathy | Persistent proteinuria/SRNS | Monitor for 1st appearance of proteinuria. |
CNS | During first 3 mos of life2 CKD | Monitor progression of known CKD. |
Disorder of testicular development 46,XX gonadal dysgenesis | Monitor timing progression of puberty. | Annually or per treating multidisciplinary team (clinical geneticist, endocrinologist, urologist, psychologist) |
Wilms tumor | Monitor for 1st appearance of Wilms tumor. | Abdominal US every 3 mos until age 7 yrs3 |
CAKUT | Follow up known kidney /or urinary tract anomalies. | Per treating nephrologist /or urologist CAKUT = congenital anomalies of the kidney and urinary tract; CKD = chronic kidney disease; CNS = congenital nephrotic syndrome; SRNS = steroid-resistant nephrotic syndrome; US = ultrasound 1. 2. 3. , , |
Source: GeneReviews — "WT1 Disorder"
Phenotype severity distribution: 9 always present features, 4 very common features, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
Nagano C (2025). [PMID: 39002031](https://pubmed.ncbi.nlm.nih.gov/39002031/). *Clin Exp Nephrol*. [Review / Meta-Analysis]
Gao S (2025). [PMID: 40980126](https://pubmed.ncbi.nlm.nih.gov/40980126/). *Front Pediatr*. [Case Report / Case Series]
Lopez-Gonzalez M (2024). [PMID: 38326647](https://pubmed.ncbi.nlm.nih.gov/38326647/). *Pediatr Nephrol*. [Review / Meta-Analysis]
Inoue S (2024). [PMID: 38877226](https://pubmed.ncbi.nlm.nih.gov/38877226/). *Clin Exp Nephrol*. [Basic Science / Preclinical]
AI-curated news mentioning Frasier syndrome
Updated Sep 28, 2026
A recent case report highlights the ultrasonographic features of the kidney in patients with Frasier syndrome and stage 5 chronic kidney disease. This study contributes to the understanding of renal manifestations in this rare genetic condition.